1. Home
  2. MYGN vs CAC Comparison

MYGN vs CAC Comparison

Compare MYGN & CAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MYGN
  • CAC
  • Stock Information
  • Founded
  • MYGN 1991
  • CAC 1875
  • Country
  • MYGN United States
  • CAC United States
  • Employees
  • MYGN N/A
  • CAC N/A
  • Industry
  • MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • CAC Major Banks
  • Sector
  • MYGN Health Care
  • CAC Finance
  • Exchange
  • MYGN Nasdaq
  • CAC Nasdaq
  • Market Cap
  • MYGN 642.0M
  • CAC 680.5M
  • IPO Year
  • MYGN 1995
  • CAC 1997
  • Fundamental
  • Price
  • MYGN $7.96
  • CAC N/A
  • Analyst Decision
  • MYGN Hold
  • CAC Buy
  • Analyst Count
  • MYGN 13
  • CAC 3
  • Target Price
  • MYGN $13.50
  • CAC $48.00
  • AVG Volume (30 Days)
  • MYGN 1.5M
  • CAC 66.9K
  • Earning Date
  • MYGN 11-06-2025
  • CAC 10-28-2025
  • Dividend Yield
  • MYGN N/A
  • CAC 4.35%
  • EPS Growth
  • MYGN N/A
  • CAC 4.80
  • EPS
  • MYGN N/A
  • CAC 3.11
  • Revenue
  • MYGN $832,900,000.00
  • CAC $197,501,000.00
  • Revenue This Year
  • MYGN $0.17
  • CAC $42.11
  • Revenue Next Year
  • MYGN $6.19
  • CAC $5.51
  • P/E Ratio
  • MYGN N/A
  • CAC $12.41
  • Revenue Growth
  • MYGN 3.83
  • CAC 21.74
  • 52 Week Low
  • MYGN $3.76
  • CAC $34.53
  • 52 Week High
  • MYGN $26.60
  • CAC $50.07
  • Technical
  • Relative Strength Index (RSI)
  • MYGN 57.10
  • CAC 46.25
  • Support Level
  • MYGN $7.04
  • CAC $37.50
  • Resistance Level
  • MYGN $8.25
  • CAC $39.54
  • Average True Range (ATR)
  • MYGN 0.38
  • CAC 0.86
  • MACD
  • MYGN -0.06
  • CAC -0.08
  • Stochastic Oscillator
  • MYGN 54.77
  • CAC 31.13

About MYGN Myriad Genetics Inc.

Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.

About CAC Camden National Corporation

Camden National Corporation is a banking solutions provider in the United States. Its core business is providing commercial banking products to individuals and corporates. Its consumer and commercial banking services entail services such as loans and deposits, savings and online banking, treasury management solutions and non-profit products to consumer, institutional, municipal, non-profit and commercial customers. The company also offers investment management and fiduciary services.

Share on Social Networks: